Physician profile
Danielle Ross
NPI 1265161335
$1,719.13
in general payments reported to CMS, 2019-2025
15 companies · $410 in 2025
The $410 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $281 · 2023: $312 · 2024: $716 · 2025: $410.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,438.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,437.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $384.73 | 2022-2024 | Eliquis, Camzyos |
| Novo Nordisk INC | $243.72 | 2022-2025 | Wegovy |
| Astrazeneca Pharmaceuticals LP | $219.34 | 2022-2024 | Wainua, Fasenra |
| Inari Medical, INC. | $172.42 | 2025 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Paratek Pharmaceuticals, INC. | $117.34 | 2025 | Nuzyra |
| Bayer Healthcare Pharmaceuticals INC. | $111.88 | 2024-2025 | |
| Abbvie INC. | $99.38 | 2023 | Dalvance |
| Gilead Sciences, INC. | $97.02 | 2024 | Veklury |
| Boston Scientific Corporation | $88.98 | 2023-2024 | Watchman Flx, Watchman Access System |
| Penumbra, INC. | $76.17 | 2024 | Indigo System |
| Janssen Pharmaceuticals, INC | $49.45 | 2024 | Xarelto |
| Merck Sharp & Dohme LLC | $15.41 | 2023 | Dificid, Zerbaxa, Recarbrio |
| Pfizer INC. | $15.16 | 2022 | |
| Mylan Specialty L.P. | $14.45 | 2024 | Yupelri |
| Myriad Women'S Health, INC. | $13.68 | 2023 | Myrisk |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danielle Ross listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.